The outlook of companies tied to the drug's past presents a intricate investment scenario . While the initial boom generated substantial returns , generic competition have significantly diminished market share . Investing in connected pharmaceutical businesses now requires a thorough assessment of patent rights , evolving healthcare trends , and th